XenoPort to present arbaclofen placarbil, XP13512 trial data at 62nd American Academy of Neurology meeting

XenoPort announced today that new data from clinical trials of its product candidates arbaclofen placarbil and XP13512 (gabapentin enacarbil) will be presented at the 62nd Annual American Academy of Neurology meeting in Toronto, Ontario. The following posters will be presented:

Arbaclofen placarbil, also known as XP19986

Spasticity

  • Arbaclofen Placarbil Is Efficacious and Safe in a Study of the Treatment of Spasticity Due to Spinal Cord Injury
    Session Info: Poster Session V: April 15, 7:30 a.m.-12:00 p.m. ET
    Poster #: P05.146

XP13512 (gabapentin enacarbil)

Moderate-to-Severe Primary Restless Legs Syndrome

  • A Randomized, Crossover Polysomnography Study of Gabapentin Enacarbil in Subjects with Moderate-to-Severe Primary Restless Legs Syndrome and Associated Sleep Disturbance
    Session Info: Poster Session II: April 13, 3:00-7:30 p.m. ET
    Poster #: P02.280
  • An Open-label, 52-Week Extension Study to Assess the Long-term Tolerability and Efficacy of Gabapentin Enacarbil in Subjects with Moderate-to-Severe Primary Restless Legs Syndrome
    Session Info: Poster Session II: April 13, 3:00-7:30 p.m. ET
    Poster #: P02.281
  • Population Pharmacokinetics and Pharmacodynamics of Gabapentin after Administration of Gabapentin Enacarbil in Subjects with Primary Restless Legs Syndrome
    Session Info: Poster Session II: April 13, 3:00-7:30 p.m. ET
    Poster #: P02.282
  • Gabapentin Enacarbil Improves Restless Legs Syndrome (RLS) Symptoms and Subjective Measures of Sleep in Subjects with Primary RLS with and without Severe Sleep Disturbance: Secondary Analyses from Two Studies
    Session Info: Poster Session II: April 13, 3:00-7:30 p.m. ET
    Poster #: P02.283
  • Gabapentin Enacarbil Relieves the Pain Associated with Restless Legs Syndrome
    Session Info: Poster Session II: April 13, 3:00-7:30 p.m. ET
    Poster #: P02.284
  • An Examination of Mood, Quality of Life, and Functioning in Subjects with Primary Restless Legs Syndrome Treated with Gabapentin Enacarbil Compared with Placebo
    Session Info: Poster Session II: April 13, 3:00-7:30 p.m. ET
    Poster #: P02.285
  • Evaluating Maintenance of Improvements in Sleep and Quality of Life in Subjects with Restless Legs Syndrome with Gabapentin Enacarbil for up to 36 Weeks
    Session Info: Poster Session II: April 13, 3:00-7:30 p.m. ET
    Poster #: P02.286
  • An Evaluation of Gabapentin Enacarbil and Restless Legs Syndrome Symptom Augmentation in Subjects Treated for 12 Weeks: Secondary Analyses from Two Studies
    Session Info: Poster Session II: April 13, 3:00-7:30 p.m. ET
    Poster #: P02.287

Post-Herpetic Neuralgia

  • A Randomized, Placebo-controlled Trial of Gabapentin Enacarbil in Subjects with Post-Herpetic Neuralgia
    Session Info: Poster Session V: April 15, 7:30 a.m.-12:00 p.m. ET
    Poster #: P05.228
Source:

XenoPort, Inc.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
You might also like... ×
Mice study identifies ventral spinocerebellar tract neurons that control locomotion